Biomerica

Biomerica FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Biomerica (BMRA) as of Oct 27, 2026 is 90.65 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 77.98 % — a change of 16.24% (higher).

FCF Conversion

90.65 %

YoY

16.24%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Biomerica is 2026 90.65 % . FCF Conversion Rate (FCF/EBITDA) of Biomerica was 2025 77.98 % . It decreases by 16.24% higher compared to the previous year.

The Biomerica FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
100.92 USD
Jan 1, 2020
188.81 USD
Jan 1, 2021
74.50 USD
Jan 1, 2022
14.36 USD
Jan 1, 2023
77.76 USD
Jan 1, 2024
91.60 USD
Jan 1, 2025
77.98 USD
Jan 1, 2026
90.65 USD
The Biomerica FCF Conversion history
YEARFCF ConversionYoY
90.65 %+16.24%
77.98 %-14.87%
91.60 %+17.80%
77.76 %+441.32%
14.36 %-80.72%
74.50 %-60.54%
188.81 %+87.09%
100.92 %+13.40%
89.00 %-1.26%
90.14 %+344.73%
20.27 %-84.39%
129.80 %-75.57%
531.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomerica Stock analysis

What does Biomerica do? Biomerica, Inc. generates revenue through the development, manufacture, and marketing of medical diagnostic products for early detection and monitoring of chronic diseases. The company sells diagnostic test kits to clinical laboratories and point-of-care markets, analyzing blood, urine, or fecal specimens to measure specific bacteria, hormones, antibodies, antigens, or other substances. Its flagship product, InFoods IBS, offers diagnostic-guided therapy to identify patient-specific foods that may alleviate Irritable Bowel Syndrome symptoms when removed from the diet. The diagnostic test kits are used by clinical laboratories and point-of-care facilities to detect diseases through specimen analysis. InFoods IBS targets physicians seeking personalized dietary solutions for IBS patients, allowing them to identify foods that improve symptoms when eliminated. Biomerica focuses on chronic disease management with products designed for early detection and monitoring in both laboratory and point-of-care settings. Biomerica's revenue streams include sales of diagnostic test kits to clinical laboratories and point-of-care markets, as well as the InFoods IBS diagnostic-guided therapy product. The company serves healthcare providers and physicians who utilize these tools for patient diagnosis and treatment planning, particularly in managing chronic conditions like IBS through dietary adjustments. Biomerica is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomerica stock

FCF Conversion Rate (FCF/EBITDA) of Biomerica is 90.65 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Biomerica changed from 77.98 % to 90.65 %, representing a 16.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Biomerica since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Biomerica with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biomerica

All Key Metrics — Biomerica